Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) Director Johnny D. Powers bought 100,000 shares of the firm's stock in a transaction on Monday, November 11th. The stock was acquired at an average price of $0.12 per share, for a total transaction of $12,000.00. Following the completion of the purchase, the director now directly owns 2,425,000 shares in the company, valued at approximately $291,000. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Zomedica Stock Performance
ZOM opened at $0.14 on Wednesday. Zomedica Corp. has a 1 year low of $0.12 and a 1 year high of $0.23.
Wall Street Analysts Forecast Growth
Separately, Noble Financial upgraded Zomedica to a "strong-buy" rating in a research report on Monday.
Check Out Our Latest Report on Zomedica
Institutional Investors Weigh In On Zomedica
Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?
From Golden Crest | Ad
Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming.
The question is: Why aren't you taking action, too?
Click Here For Your Free Guide
An institutional investor recently raised its position in Zomedica stock. Price T Rowe Associates Inc. MD lifted its stake in Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) by 41.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 948,300 shares of the company's stock after purchasing an additional 276,100 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.10% of Zomedica worth $139,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 8.95% of the company's stock.
Zomedica Company Profile
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
